ArticleBiosensors2022
A Portable Nanoprobe for Rapid and Sensitive Detection of SARS-CoV-2 S1 Protein.
Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Development and Evaluation of a Nanoparticle-Based Immunoassay for Rotavirus Detection: A Suitable Alternative to ELISA and PCR in Low-Income Setting.Methods and protocols · 2025Article
- Advancing protein biosensors: redefining detection through innovations in materials, mechanisms, and applications for precision medicine and global diagnostics.RSC advances · 2025Review
- Article
- Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials.Nano convergence · 2024Review
- Article
- Development of Rapid Aptamer-Based Screening Assay for the Detection of Covid-19 Variants.ACS omega · 2023Article
- Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2.Analytical biochemistry · 2023Review
- MICaFVi: A Novel Magnetic Immuno-Capture Flow Virometry Nano-Based Diagnostic Tool for Detection of Coronaviruses.Biosensors · 2023Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Simple, timely, and precise detection of SARS-CoV-2 in clinical samples and contaminated surfaces aids in lowering attendant morbidity/mortality related to this infectious virus. Currently applied diagnostic techniques depend on a timely laboratory report following PCR testing. However, the application of these tests is associated with inherent shortcomings due to the need for trained personnel, long-time centralized laboratories, and expensive instruments. Therefore, there is an interest in developing biosensing diagnostic frontiers that can help in eliminating these shortcomings with a relatively economical, easy-to-use, well-timed, precise and sensitive technology. This study reports the development of fabricated Q-tips designed to qualitatively and semi-quantitatively detect SARS-CoV-2 in clinical samples and contaminated non-absorbable surfaces. This colorimetric sensor is engineered to sandwich SARS-CoV-2 spike protein between the lactoferrin general capturing agent and the complementary ACE2-labeled receptor. The ACE2 receptor is decorated with an orange-colored polymeric nanoparticle to generate an optical visual signal upon pairing with the SARS-CoV-2 spike protein. This colorimetric change of the Q-tip testing zone from white to orange confirms a positive result. The visual detection limit of the COVID-19 engineered colorimetric Q-tip sensor was 100 pfu/mL within a relatively short turnaround time of 5 min. The linear working range of quantitation was 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.